These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 21810100)

  • 1. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets.
    Chudy M; Weber-Schehl M; Pichl L; Jork C; Kress J; Heiden M; Funk MB; Nübling CM
    Transfusion; 2012 Feb; 52(2):431-9. PubMed ID: 21810100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing.
    Müller B; Nübling CM; Kress J; Roth WK; De Zolt S; Pichl L
    Transfusion; 2013 Oct; 53(10 Pt 2):2422-30. PubMed ID: 23782012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First report of human immunodeficiency virus transmission via an RNA-screened blood donation.
    Delwart EL; Kalmin ND; Jones TS; Ladd DJ; Foley B; Tobler LH; Tsui RC; Busch MP
    Vox Sang; 2004 Apr; 86(3):171-7. PubMed ID: 15078251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.
    Nübling CM; Heiden M; Chudy M; Kress J; Seitz R; Keller-Stanislawski B; Funk MB
    Transfusion; 2009 Sep; 49(9):1850-8. PubMed ID: 19453976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection.
    Busch MP; Glynn SA; Wright DJ; Hirschkorn D; Laycock ME; McAuley J; Tu Y; Giachetti C; Gallarda J; Heitman J; Kleinman SH;
    Transfusion; 2005 Dec; 45(12):1853-63. PubMed ID: 16371038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations.
    Bamaga MS; Bokhari FF; Aboud AM; Al-Malki M; Alenzi FQ
    Saudi Med J; 2006 Jun; 27(6):781-7. PubMed ID: 16758035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
    Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
    Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.
    Schmidt M; Korn K; Nübling CM; Chudy M; Kress J; Horst HA; Geusendam G; Hennig H; Sireis W; Rabenau HF; Doerr HW; Berger A; Hourfar MK; Gubbe K; Karl A; Fickenscher H; Tischer BK; Babiel R; Seifried E; Gürtler L
    Transfusion; 2009 Sep; 49(9):1836-44. PubMed ID: 19453990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative distribution of West Nile virus RNA in blood compartments: implications for blood donor nucleic acid amplification technology screening.
    Lai L; Lee TH; Tobler L; Wen L; Shi P; Alexander J; Ewing H; Busch M
    Transfusion; 2012 Feb; 52(2):447-54. PubMed ID: 21827506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.
    Chudy M; Kress J; Halbauer J; Heiden M; Funk MB; Nübling CM
    Transfus Med Hemother; 2014 Feb; 41(1):45-51. PubMed ID: 24659947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.
    Katsoulidou A; Moschidis Z; Sypsa V; Chini M; Papatheodoridis GV; Tassopoulos NC; Mimidis K; Karafoulidou A; Hatzakis A
    Vox Sang; 2007 Jan; 92(1):8-14. PubMed ID: 17181585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period.
    Ling AE; Robbins KE; Brown TM; Dunmire V; Thoe SY; Wong SY; Leo YS; Teo D; Gallarda J; Phelps B; Chamberland ME; Busch MP; Folks TM; Kalish ML
    JAMA; 2000 Jul; 284(2):210-4. PubMed ID: 10889595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?
    Stramer SL; Zou S; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY
    Transfusion; 2012 Feb; 52(2):440-6. PubMed ID: 21810101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
    Nantachit N; Thaikruea L; Thongsawat S; Leetrakool N; Fongsatikul L; Sompan P; Fong YL; Nichols D; Ziermann R; Ness P; Nelson KE
    Transfusion; 2007 Oct; 47(10):1803-8. PubMed ID: 17880604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus 1 dual-target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden-Württemberg-Hessen.
    Hourfar K; Eberle J; Müller M; Micha Nübling C; Chudy M; Kress J; Gürtler L; Mayr-Wohlfart U; Schrezenmeier H; Hellmann I; Luhm J; Kraas S; Ringwald J; Gubbe K; Frank K; Karl A; Tonn T; Jaeger M; Sireis W; Seifried E; Schmidt M
    Transfusion; 2018 Dec; 58(12):2886-2893. PubMed ID: 30325043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.
    Stramer SL; Glynn SA; Kleinman SH; Strong DM; Caglioti S; Wright DJ; Dodd RY; Busch MP;
    N Engl J Med; 2004 Aug; 351(8):760-8. PubMed ID: 15317889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA.
    McCormick MK; Dockter J; Linnen JM; Kolk D; Wu Y; Giachetti C
    J Clin Virol; 2006 Jul; 36(3):166-76. PubMed ID: 16427802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China.
    Shang G; Yan Y; Yang B; Shao C; Wang F; Li Q; Seed CR
    Transfus Apher Sci; 2009 Aug; 41(1):3-7. PubMed ID: 19487161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors.
    Dettori S; Candido A; Kondili LA; Chionne P; Taffon S; Genovese D; Iudicone P; Miceli M; Rapicetta M
    J Infect; 2009 Aug; 59(2):128-33. PubMed ID: 19586663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.